180 related articles for article (PubMed ID: 32419364)
1. Clinical and immunological features of platelet transfusion refractoriness in young patients with de novo acute myeloid leukemia.
Hu X; Cai H; Zheng L; Luo Y; Zhou J; Hui Y; Dai Z; Lin H; Li D; Xiao Y; Huang L; Zhou J
Cancer Med; 2020 Jul; 9(14):4941-4948. PubMed ID: 32419364
[TBL] [Abstract][Full Text] [Related]
2. Exploration of risk factors of platelet transfusion refractoriness and its impact on the prognosis of hematopoietic stem cell transplantation: a retrospective study of patients with hematological diseases.
Song X; Qi J; Li X; Zhou M; He J; Chu T; Han Y
Platelets; 2023 Dec; 34(1):2229905. PubMed ID: 37409458
[TBL] [Abstract][Full Text] [Related]
3. Platelet transfusion refractoriness in patients with acute myeloid leukemia treated by intensive chemotherapy.
Comont T; Tavitian S; Bardiaux L; Fort M; Debiol B; Morère D; Bérard E; Delabesse E; Luquet I; Martinez S; Huguet F; Récher C; Bertoli S
Leuk Res; 2017 Oct; 61():62-67. PubMed ID: 28910610
[TBL] [Abstract][Full Text] [Related]
4. Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center.
Duan W; Liu X; Zhao X; Jia J; Wang J; Gong L; Jiang Q; Zhao T; Wang Y; Zhang X; Xu L; Shi H; Chang Y; Liu K; Huang X; Qin Y; Jiang H
Ann Hematol; 2021 May; 100(5):1203-1212. PubMed ID: 33474629
[TBL] [Abstract][Full Text] [Related]
5. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
[TBL] [Abstract][Full Text] [Related]
6. Severe Platelet Transfusion Refractoriness in Association with Antibodies Against CD36.
Schmidt AE; Sahai T; Refaai MA; Sullivan M; Curtis BR
Lab Med; 2020 Sep; 51(5):540-544. PubMed ID: 31925433
[TBL] [Abstract][Full Text] [Related]
7. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
[TBL] [Abstract][Full Text] [Related]
8. Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation.
Toor AA; Choo SY; Little JA
Bone Marrow Transplant; 2000 Aug; 26(3):315-20. PubMed ID: 10967572
[TBL] [Abstract][Full Text] [Related]
9. Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study.
Rogers HJ; Wang X; Xie Y; Davis AR; Thakral B; Wang SA; Borthakur G; Cantu MD; Margolskee EM; Philip JKS; Sukhanova M; Bagg A; Bueso-Ramos CE; Orazi A; Arber DA; Hsi ED; Hasserjian RP
Am J Hematol; 2020 Jul; 95(7):799-808. PubMed ID: 32249963
[TBL] [Abstract][Full Text] [Related]
10. RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.
Kim T; Moon JH; Ahn JS; Ahn SY; Jung SH; Yang DH; Lee JJ; Shin MG; Choi SH; Lee JY; Tyndel MS; Lee HY; Kim KH; Cai Y; Lee YJ; Sohn SK; Min YH; Cheong JW; Kim HJ; Zhang Z; Kim DDH
Sci Rep; 2020 Nov; 10(1):20119. PubMed ID: 33208771
[TBL] [Abstract][Full Text] [Related]
11. The clinical mutatome of core binding factor leukemia.
Opatz S; Bamopoulos SA; Metzeler KH; Herold T; Ksienzyk B; Bräundl K; Tschuri S; Vosberg S; Konstandin NP; Wang C; Hartmann L; Graf A; Krebs S; Blum H; Schneider S; Thiede C; Middeke JM; Stölzel F; Röllig C; Schetelig J; Ehninger G; Krämer A; Braess J; Görlich D; Sauerland MC; Berdel WE; Wörmann BJ; Hiddemann W; Spiekermann K; Bohlander SK; Greif PA
Leukemia; 2020 Jun; 34(6):1553-1562. PubMed ID: 31896782
[TBL] [Abstract][Full Text] [Related]
12. Pretransplant platelet transfusion refractoriness is not associated with platelet nonengraftment in T-replete hematopoietic progenitor cell transplantation for hematologic malignancies.
Scott A; Baidya S; Butler J; Morris K; Thornton A; Kennedy GA
Transfusion; 2016 Jan; 56(1):164-9. PubMed ID: 26264674
[TBL] [Abstract][Full Text] [Related]
13. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
Yalniz FF; Patel KP; Bashir Q; Marin D; Ahmed S; Alousi AM; Chen J; Ciurea SO; Rezvani K; Popat UR; Shpall EJ; Champlin RE; Oran B
Cancer; 2020 May; 126(10):2183-2192. PubMed ID: 32101640
[TBL] [Abstract][Full Text] [Related]
14. Refractoriness to platelet transfusions in children with acute leukemia.
DeCoteau J; Haddad S; Blanchette V; Poon A
J Pediatr Hematol Oncol; 1995 Nov; 17(4):306-10. PubMed ID: 7583385
[TBL] [Abstract][Full Text] [Related]
15. Therapy-related core binding factor acute myeloid leukemia.
George B; Yohannan B; Mohlere V; Gonzalez A
Int J Hematol Oncol; 2023 Feb; 12(1):IJH43. PubMed ID: 36874378
[TBL] [Abstract][Full Text] [Related]
16. [Genetic abnormalities in core binding factor acute myeloid leukemia].
Ishikawa Y
Rinsho Ketsueki; 2017; 58(8):991-998. PubMed ID: 28883285
[TBL] [Abstract][Full Text] [Related]
17. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
[TBL] [Abstract][Full Text] [Related]
18. Evaluation and management of platelet transfusion refractoriness.
Youk HJ; Hwang SH; Oh HB; Ko DH
Blood Res; 2022 Apr; 57(S1):6-10. PubMed ID: 35483919
[TBL] [Abstract][Full Text] [Related]
19. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
Fischer J; Rossetti S; Datta A; Eng K; Beghini A; Sacchi N
Mol Cancer; 2015 Jan; 14():7. PubMed ID: 25612891
[TBL] [Abstract][Full Text] [Related]
20. Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.
Metzeler KH; Bloomfield CD
Adv Exp Med Biol; 2017; 962():175-199. PubMed ID: 28299658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
